Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting the KRAS Pathway in Non-Small Cell Lung Cancer.

The oncologist - 1 Dec 2016

Tomasini Pascale, Walia Preet, Labbe Catherine, Jao Kevin, Leighl Natasha B

Abstract excerpt

: Lung cancer remains the leading cause of cancer-related deaths worldwide. However, significant progress has been made individualizing therapy based on molecular aberrations (e.g., EGFR, ALK) and pathologic subtype. KRAS is one of the most frequently mutated genes in non-small cell lung cancer (NSCLC), found in approximately 30% of lung adenocarcinomas, and is thus an appealing target for new therapies. Although...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HSP90 Heat-Shock Proteins
Share to Mitogen-Activated Protein Kinase Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phosphoinositide-3 Kinase Inhibitors

Share to Protein Processing, Post-Translational

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins c-met

Share to Proto-Oncogene Proteins p21(ras)

Share to TOR Serine-Threonine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 27807303
DOI: 10.1634/theoncologist.2015-0084
PMCID: PMC5153335

Genes

KRAS
ALK
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting the KRAS Pathway in Non-Small Cell Lung Cancer.PMID 27807303Read ↗

Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future.Semantic proximity Read ↗

KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target.Semantic proximity Read ↗

Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications.Semantic proximity Read ↗

Targeting KRASG12D mutation in non-small cell lung cancer: molecular mechanisms and therapeutic potential.Semantic proximity Read ↗

Targeting KRAS-mutant non-small cell lung cancer: challenges and opportunities.Semantic proximity Read ↗

KRAS mutant lung cancer: progress thus far on an elusive therapeutic targetSemantic proximity Read ↗

First-line treatments for KRAS-mutant non-small cell lung cancer: current state and future perspectives.Semantic proximity Read ↗

[Research Progress of KRAS Mutation in Non-small Cell Lung Cancer].Semantic proximity Read ↗

[Current status and outlook of medical treatment for KRAS-mutated non-small cell lung cancer].Semantic proximity Read ↗

KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures.Semantic proximity Read ↗

Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer: A Review.Semantic proximity Read ↗

KRAS mutations in non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.